Answers are grounded in this paper and cite their sources.
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, and its progression involves multiple biological processes. Rhodiola rosea has attracted increasing attention owing to its diverse pharmacological activities; however, the potential anti-NSCLC mechanisms and key active compounds of Rhodiola rosea remain insufficiently elucidated. This study aimed to develop an integrated computational and experimental framework to explore potential anti-NSCLC targets and cellular effects of Rhodiola rosea. Integrated analysis of network pharmacology and NSCLC transcriptomic data identified seven active compounds of Rhodiola rosea: 7-hydroxycoumarin, caffeic acid, kaempferol, 3,4,5-trihydroxybenzoic acid, salidroside, ethyl gallate, and tyrosol. The same analysis identified seven candidate hub proteins: AURKA, CCNA2, CHEK1, KIF11, MMP9, TK1, and TYMS. Molecular docking and molecular dynamics simulations suggested that these compounds could occupy the corresponding binding pockets and maintain stable poses during simulation. In A549 cells, salidroside reduced cell viability, induced apoptosis, increased reactive oxygen species (ROS), and decreased mitochondrial membrane potential. Western blotting showed that salidroside reduced the abundance of KIF11/Eg5, MMP9, AURKA, CCNA2, CHEK1, TK1, and TYMS in A549 cells, with concordant reductions in H1975 cells. Similar dose-dependent changes in viability, apoptosis, ROS, and mitochondrial membrane potential were also observed in H1975 cells, and BEAS-2B viability was assessed in parallel. These in vitro findings support a potential association between salidroside exposure and these cellular changes, but do not establish direct target engagement or a causal ROS-dependent mechanism.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: